Problems with UK government's risk sharing scheme for assessing drugs for multiple sclerosis

The government plans to make interferon beta and glatiramer available to patients with multiple sclerosis through a risk sharing scheme, despite lack of evidence of cost effectiveness. Sudlow and colleagues argue that the money would be better spent on independent research

Saved in:
Bibliographic Details
Published in:BMJ 2003-02, Vol.326 (7385), p.388-392
Main Authors: Sudlow, Cathie L M, Counsell, Carl E
Format: Article
Language:English
Subjects:
Bias
Biological and medical sciences
Clinical Trials as Topic
Cost effectiveness analysis
Cost efficiency
Cost estimation models
Cost-Benefit Analysis
Disabilities
Drug Evaluation - economics
Drug therapy
Education And Debate
Government
Health economics
Humans
Immunomodulators
Interferons
Medical sciences
Multiple sclerosis
Multiple Sclerosis - drug therapy
Multiple Sclerosis - economics
Multiple sclerosis and variants. Guillain barré syndrome and other inflammatory polyneuropathies. Leukoencephalitis
Neurology
Pharmacology. Drug treatments
Quality-Adjusted Life Years
Relapse
Relapsing remitting multiple sclerosis
Risk Sharing, Financial
Spreading risk
United Kingdom
Citations: Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:The government plans to make interferon beta and glatiramer available to patients with multiple sclerosis through a risk sharing scheme, despite lack of evidence of cost effectiveness. Sudlow and colleagues argue that the money would be better spent on independent research
ISSN:0959-8138
0959-8146
1468-5833
1756-1833
DOI:10.1136/bmj.326.7385.388